Gain Therapeutics’ (GANX) Buy Rating Reiterated at HC Wainwright

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 351.98% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Weiss Ratings downgraded shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Roth Capital reiterated a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and issued a $5.00 target price on shares of Gain Therapeutics in a research note on Tuesday, August 11th. Finally, Wall Street Zen upgraded Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $1.77 on Monday. The company has a market capitalization of $77.24 million, a P/E ratio of -3.54 and a beta of 0.19. Gain Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $4.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36. The stock has a 50 day moving average price of $1.85 and a two-hundred day moving average price of $1.94.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. Analysts expect that Gain Therapeutics will post -0.5 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after purchasing an additional 8,251 shares during the period. Marshall Wace LLP raised its stake in Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after buying an additional 80,407 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Gain Therapeutics in the third quarter worth about $47,000. Squarepoint Ops LLC purchased a new stake in Gain Therapeutics in the third quarter worth about $68,000. Finally, Virtu Financial LLC boosted its position in Gain Therapeutics by 126.9% during the 3rd quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock valued at $96,000 after acquiring an additional 30,207 shares in the last quarter. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.